DOI: 10.1093/bjd/ljag458 ISSN: 0007-0963
Defining Core Outcome Domain Items for Pyoderma Gangrenosum Clinical Trials: Results From the PRECISE-PG International Delphi Consensus Study on Behalf of UPGRADE
Katelyn Downey, Mike Jacobson, Nazgol-Sadat Haddadi, David O Croitoru, Angelo V Marzano, Erkan Alpsoy, Jenny Belén Altamirano-Jara, Linda Benskin, Jean L Bolognia, Rebecca Byler, Jeffrey P Callen, Diana M Chen, Dave DePottie, Valentina Dini, Mabrouk Elgadi, Alireza Firooz, Joao Renato Vianna Gontijo, Lisa Gould, Nutan Gowda, Giammarco Granieri, Philip J Hampton, Mihaly Imre, Kirsi Isoherranen, Robert Kelly, Antonios G A Kolios, Jette Marcussen, Barbara Nolan, Deborah Oakes, Hyunsun Park, Samantha Polly, Sahand Rahnama-Moghadam, Catalina Rincón Pérez, Maria Cecilia Rivitti-Machado, Sheila Shaigany, Cathryn Sibbald, Yayoi Tada, George S Tiplica, Stanislav N Tolkachjov, Corlis V Watkins-Nass, Keiichi Yamanaka, Siri P Zelander, Louise A A Gerbens, Cecilia A C Prinsen, Alex G Ortega-LoayzaAn international, multistakeholder modified Delphi process was used to establish core outcome domain items for pyoderma gangrenosum clinical trials. Following three survey rounds and consensus meetings, 11 items reached final ratification, providing a standardized, patient-centered framework for outcome assessment and improved comparability across future trials.